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Abstract:  
Background & Aims: Consumption of sweetened beverages has been associated with 
inflammation, based on measurements of C-reactive protein and tumor necrosis factor, as 
well as immune-mediated disorders including rheumatoid arthritis. We investigated 
associations with Crohn’s disease (CD) or ulcerative colitis (UC). 
 
Methods: We conducted a prospective cohort study of 83,042 participants (44–83 years 
old) enrolled in the Cohort of Swedish Men or the Swedish Mammography Study. 
Dietary and lifestyle data were collected using a validated food frequency questionnaire 
at baseline in 1997. Diagnoses of CD and UC were ascertained from the Swedish Patient 
Register. We used Cox proportional hazards modeling to calculate hazard ratios (HR) and 
95% CIs. 
 
Results: Through December of 2014, we confirmed 143 incident cases of CD (incidence 
rate = 11 cases/100,000 person-years) and 349 incident cases of UC (incidence rate = 28 
cases/100,000 person-years) over 1,264,345 person-years of follow up. Consumption of 
sweetened beverages was not associated with increased risk of CD (Ptrend = 0.34) or UC 
(Ptrend = 0.40). Compared to participants who reported no consumption of sweetened 
beverages, the multivariable-adjusted HRs for 1 or more servings per day were 1.02 
for CD (95% CI, 0.60–1.73) and 1.14 for UC (95% CI, 0.83–1.57). The association 
between consumption of sugar-sweetened beverages and risk of CD or UC were not 
modified by 
age, sex (cohort), body mass index, or smoking (all Pinteraction ≥ 0.12). 
 
Conclusion: In analyses of data from 2 large prospective cohort studies from Sweden, we 
observed no evidence for associations between consumption of sweetened beverages and 
later risk of CD or UC 
 
KEY WORDS: CoSM, SMC, IBD, BMI; epidemiology 
 
Editor’s Notes 
Background 
Consumption of sweetened beverage has been associated with systemic inflammation and 
immune-mediated disorders such as rheumatoid arthritis. We analyzed data from 2 large 
cohorts in Sweden to determine whether consumption was associated with risk of CD or 
UC. 
 
Findings 
We observed no evidence for associations between consumption of sweetened beverages 
and later risk of CD or UC. 
 
Implications  
Consumption of sweetened beverages does not appear to increase risk of CD or UC. 
Studies are needed to determine the effects on disease progression in patients who 
already have these diseases. 
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INTRODUCTION:  
Crohn’s disease (CD) and ulcerative colitis (UC), collectively known as 
inflammatory bowel disease (IBD), are chronic inflammatory bowel disorders of the 
gastrointestinal tract with rising global incidence, particularly in recently industrialized 
countries[1, 2]. Westernization of diet has been implicated in the pathogenesis of IBD[3]. 
Nevertheless, epidemiologic studies of diet have yielded very few promising leads.   
Increasing consumption of sweetened beverages has been linked to the growing 
epidemic of obesity and metabolic-related disorders [4-7]. In parallel, there is mounting 
evidence for the critical role of obesity in chronic inflammatory disorders of the 
gastrointestinal tract, particularly CD [8-10]. Additionally, a number of studies have 
demonstrated a positive association between consumption of sweetened beverages and 
systemic inflammation as measured by C-reactive protein (CRP) [11, 12]. In turn, we 
have previously shown that higher prediagnostic levels of circulating CRP are associated 
with risk of incident CD[13].  
A recent study from the European Prospective Investigation into Cancer and 
Nutrition (EPIC) demonstrated that a dietary pattern consisting of high consumption of 
sugar and sweetened beverages and low consumption of vegetables is associated with 
increased risk of UC[14]. Nevertheless, there has been no comprehensive examination of 
the association between consumption of sweetened beverage and risk of incident CD and 
UC.  
We therefore sought to examine the association between consumption of 
sweetened-beverages and risk of CD and UC in two large prospective cohort studies in 
Sweden, the Swedish Mammography Study (SMC) and the Cohort of Swedish Men 
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(CoSM). With detailed and validated data on dietary information on over 80,000 men and 
women with linkage to Swedish Patient Register, these cohorts offered us a unique 
opportunity to examine this relationship while adjusting for other potential lifestyle and 
dietary factors. 
METHODS:  
Study population:  
SMC is a population-based cohort from the Uppsala county of central Sweden 
which was established between 1987 and 1990 when 66,651 women returned completed 
questionnaires on diet, alcohol, weight, height, medications use, and reproductive and 
menopausal factors.  Follow up questionnaires were sent in 1997, 2008, and 2009 and 
were expanded to include data on smoking, physical activity, medical history, and family 
history.  CoSM is a parallel population-based cohort of 45,906 middle-aged and elderly 
men established in Central Sweden (Västmanland and Örebro Counties) in the fall of 
1997. At baseline, participants provided information on lifestyle factors such as diet, 
physical activity, smoking, weight, and use of a number of specified medications through 
a mailed questionnaire similar to that of SMC. Follow up questionnaires were sent to 
participants in 2008 and 2009.  For this study, we included participants who had 
completed the 1997 questionnaires in both cohorts, which included all participants in 
CoSM and women in SMC who were still alive in 1997 and returned the dietary 
questionnaire (n = 38,984, 70% response rate). We excluded men and women who did 
not provide information on diet or those with diagnosis of IBD at baseline (Figure 1).  
We also excluded participants with implausible total caloric intake defined by intakes not 
within three standard divisions of the log transformed mean.  
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Primary Exposure and Other Covariates: 
Dietary information was collected using a 96-item semiquantitative food 
frequency questionnaire (SFFQ) at baseline in 1997 in both cohorts. SFFQ specifically 
asked participants to report their usual consumption, during the past year, of a standard 
glass (200 mL) of sweetened beverages in the form of soft drinks per day or week. 
Although in the 1997 questionnaire, no distinction was made between sugar-sweetened 
(Coca Cola, Pepsi, etc.) and artificially sweetened beverages (Diet Coca Cola, Diet Pepsi, 
etc), according to Swedish national consumption data, artificially-sweetened soft drinks 
accounted for less than 10% and 20% of all soft drinks among men and women, 
respectively[15]. Sweetened beverages also did not include fruit juices, syrups, energy 
and sports drinks, or sweetened coffee, tea, or milk.  
Intakes of nutrients were calculated using composition values from the Swedish 
Food Administration Database and were adjusted for total caloric intake using the 
residual model. The SFFQ has been validated against fourteen 24-hr diet recall interviews 
done over one year period in a subset of participants in CoSM (n = 248).  The Spearman 
coefficient correlation ranged between 0.70 to 0.73 for intakes of total carbohydrate, fat, 
fiber, and sucrose (primary sugar in soft drinks)[16]. In SMC, the SFFQ (version from 
1987 similar to that used in CoSM and SMC in 1997) has been validated against four 
one-week diet records done over one year period in 129 women[17]. The Spearman 
correlation coefficient between SFFQ and diet records for sweetened beverage was 0.60.  
Outcome Ascertainment:  
 The Swedish National Board of Health and Welfare has collected individual-level 
data on hospital discharges on a countywide level since 1964 (nationwide since 
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1987)[18]. Each record, organized according to an individual's personal identity number, 
includes date of birth, sex, dates of hospital admission, hospital department, and 
discharge diagnoses (including surgical procedures), coded according to the International 
Classification of Diseases[19]. Since 2001, this registry was expanded to include 
specialized outpatient care[18].  
 Incident cases of CD and UC were identified by linkage of SMC and CoSM 
participants to the nationwide registry. Incident cases were defined by at least two 
inpatient or outpatient encounters with a primary or secondary diagnosis (for UC ICD9: 
‘556’ or ICD10: ‘K51’; for CD ICD9: 555 or ICD10: K50) after the return of the 1997 
questionnaires in each cohort. The accuracy of ICD coding for the ascertainment of a 
number of chronic diseases, including IBD, for the inpatient component of the National 
Patient Register has been previously validated, with a positive predictive value of 85-
95% [20].  Additionally, a recent validation study demonstrated that the positive 
predictive values using this definition for CD, UC, and IBD cases were 81%, 90%, and 
93% respectively[21]. 
Statistical Analysis: 
 We examined the possibility that there is a non-linear association between 
consumption of sweetened-beverages and risk of CD and UC using a previously reported 
non-parametic cubic spline method,[22] which also permits controlling for covariates and 
stepwise selection among spline variables. This analysis provides p-values from the 
likelihood ratio tests for non-linearity, a linear relation, and any relation. Using this 
method, the likelihood ratio tests comparing models with linear terms with those with 
spline terms were not statistically significant (All Pcomparisons > 0.48), indicating absence 
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of non-linear associations between consumption of sweetened-beverages and risk of CD 
and UC. 
Person-time was calculated from January 1, 1998 to date of diagnosis, emigration, 
death, or end of follow up (January 1, 2015), whichever came first. Categories of 
sweetened beverage consumption were created according to number of servings, which 
best approximated quartiles of daily consumption (0, 0.1-0.4, 0.5-0.9, ≥ 1 servings/day). 
We used Cox proportional hazard modeling to estimate the age- and multivariable-
adjusted hazard ratio (HR) and 95% confidence interval (CI). Our models were adjusted 
for age, body mass index (BMI), smoking, total caloric intake, total protein intake, total 
fiber intake, and non-steroidal anti-inflammatory drugs (NSAIDs) use (number of tablets 
per week).  Additionally, all models were stratified by sex/cohort. Test for trend across 
categories was done by assigning the median value to each category and modeling this as 
a continuous variable.  
We performed multiple sensitivity and exploratory analyses. First, we restricted 
our follow up to after January 2002, excluding all IBD cases prior to this date, to allow 
for a one-year lag between introduction of outpatient data in the National Patient Register 
and identification of prevalent cases of IBD previously not captured through 
hospitalizations. In addition, this analysis allowed us to explore the possibility that 
symptoms related to subclinical or early disease may have altered individual’s tendency 
to consume sweetened beverage. Second, we further adjusted our analysis for total 
sucrose intake, the primary sugar in sweetened beverages, to further examine the 
independent association between sweetened beverage and risk of IBD. Lastly, we 
examined the possibility that the association between sweetened beverage and risk of 
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IBD may be modified by age, sex, BMI, and smoking. We tested for the significance of 
the interaction by entering sweetened beverage consumption and these covariates in our 
models as multiplicative interaction terms. We also estimated the minimum detectable 
HR for CD and UC assuming 80% power and an alpha of 0.05 using described methods 
[23].  We tested for the proportional hazards assumption by examination of the 
interaction between age in categories and sweetened beverage consumption in quartiles 
and observed no violations (all p > 0.65). We used SAS version 9.4 (Cary, NC) for these 
analyses. All P-values were 2-sided and < 0.05 was considered statistically significant. 
The study was approved by the regional ethics committee of Stockholm, Sweden. 
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RESULTS: 
 
 Through till the end of December 2014, we confirmed 349 incident cases of UC 
(incidence rate = 28 cases/100,000 person-years) and 143 incident cases of CD (incidence 
rate = 11 cases/100,000 person-years) among 83,042 participants over 1,264,345 person-
years with a mean follow up of 11 years. The age of diagnosis of UC and CD cases 
ranged from 44 to 92 years.  Baseline characteristics of participants are reported in Table 
1. The median age of participants at baseline was 60 years (range: 44-83 years). 
Compared to non-consumers of sweetened beverages, participants with one or more 
serving per day were on average more likely to have used NSAIDs and had a higher 
caloric intake. However, there were no differences in age, BMI, smoking, total intake of 
protein, fiber, or fat comparing non-consumers to participants in the highest quartile of 
sweetened beverage intake.  
 Higher consumption of sweetened beverage was not associated with increased 
risk of UC (Ptrend = 0.13) (Table 2). Compared to non-consumer, the age-adjusted HR of  
UC among participants with ≥ 1 serving per day of sweetened beverage was 1.26 (95% 
CI, 0.93-1.69). These estimates were not materially altered after adjusting for other 
covariates (Ptrend = 0.40).  Compared to non-consumers, the MV-adjusted HR of UC 
among participants with ≥ 1 serving per day of sweetened beverage was 1.14 (95% 0.83-
1.57). Similarly, we did not observe an association between higher consumption of 
sweetened beverage and risk of CD (Ptrend = 0.11) (Table 2). Compared to non-
consumers, the age-adjusted HR of CD among participants with ≥ 1 serving per day of 
sweetened beverage was 1.18 (95% CI, 0.72-1.73). These estimates were not materially 
altered after adjusting for other potential confounders (Ptrend = 0.34).  Compared to non-
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consumers, the MV-adjusted HR of CD among participants with ≥ 1 serving per day of 
sweetened beverage was 1.02 (95% CI 0.60-1.73).  We also repeated our main analyses 
examining the risk of CD and UC among ever users of sweetened beverage compared to 
non-users and observed similar results. Compared to non-users, ever users had 
multivariable-adjusted HRs of 1.20 (95% CI 0.85-1.69) for CD  and 1.03 (95% CI 0.83-
1.28).  
 In our sensitivity analyses restricting our follow up to after January 2002, one 
year after the patient registry was expanded to include outpatient diagnoses, our results 
remained consistent (All Ptrend > 0.69). Compared to non-users, the MV-adjusted HRs of 
CD and UC among participants with ≥ 1 serving per day were 0.82 (95% CI 0.43-1.59) 
and 1.10  (95% CI 0.75-1.61), respectively. We also explored the association between 
sweetened beverage and risk of CD and UC, independent of its primary sugar component 
by adjusting our models for total sucrose intake and observed no significant associations. 
Compared to non-users, the MV-adjusted HRs of CD and UC among participants with ≥ 
1 serving per day were 1.13 (95% CI 0.59-2.14, Ptrend = 0.21) and 1.09  (95% CI 0.74-
1.61, Ptrend = 0.67), respectively. 
 We explored whether the association between consumption of sweetened 
beverages and risk of CD and UC are modified by age, sex (cohort), smoking, or BMI 
(Tables 3 and 4) and observed no evidence for effect modification (All Pinteraction > 0.12).  
Finally, we explored whether the association between sweetened beverage and risk of UC 
is limited to participants with low fiber intake as demonstrated in one prior study from 
the European Prospective Investigation into Cancer and Nutrition[14]. Among 
participants with lower than median intake of fiber, the MV-adjusted risk of UC with 
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each daily serving of sweetened beverage was 0.97 (95% CI 0.85-1.11). In addition, there 
was no evidence of effect modification by fiber intake on the association between 
sweetened beverage intake and risk of UC (Pinteraction = 0.93). Finally, in analyses 
restricting diagnosis to elderly-onset IBD (age ≥ 60 years), we observed no associations 
between sweetened beverage and risk of CD or UC. Compared to non-users, the MV-
adjusted HRs of CD and UC for every one serving increase in sweetened beverage were 
0.98 (95% CI 0.85-1.14) and 1.05  (95% CI 0.98-1.13), respectively. 
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DISCUSSION: 
 In two large prospective cohorts in Sweden, we found no association between 
consumption of sweetened-beverage and risk of CD or UC. The findings were consistent 
across several sensitivity analyses and among various subgroups.   
Consumption of sweetened-beverages has previously been linked to a number of 
metabolic syndromes including type 2 diabetes and cardiovascular disease[4-6, 12]. 
Much of these associations have been attributed to the presence of high sucrose, fructose, 
and corn syrup in sweetened-beverages, which in turn are linked to weight gain and 
increased insulin resistance. US Preventive Services Task Force has identified higher 
consumption of sweetened beverage as a dietary factor that at least in part explains the 
increasing rate of obesity in childhood and adolescence[24, 25]. More recently a number 
of studies have also demonstrated a link between consumption of sweetened beverages 
and higher levels of inflammatory markers such as C-reactive protein, IL-6, and TNF 
receptor 2[11, 12]. Consistent with this observation, an analysis from the Nurses’ Health 
Study demonstrated that sugar-sweetened soda is associated with increased risk of 
seropositive rheumatoid arthritis[26]. Interestingly in that study the risk was particularly 
higher in those with later onset disease (age ≥ 55 years). Nevertheless, two randomized 
controlled trials have demonstrated no association between sweetened beverage and 
measures of inflammatory markers including C-reactive protein and IL-6[27, 28]. 
Additionally, a recent study by Kuzma and colleagues did not find any changes in 
measures of inflammation in adipose tissue with intakes of sweetened beverage[27]. 
These observations are in line with our finding of a lack of an association between 
sweetened beverage and risk of CD or UC. Nevertheless, as the mean age of IBD 
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diagnosis in our cohorts was greater than 60 years, future studies examining the role of 
sweetened beverage in younger-onset CD and UC are needed to examine whether 
particular subgroups may be at risk.  
We acknowledge several limitations. First, at baseline we did not collect 
information on use of artificial sweeteners. However based on the Swedish national 
consumption data, these beverages accounted for a small proportion of use in Sweden in 
1997. We also did not have updated dietary data over the study period and therefore were 
not able to account for changes in patterns of use over the follow up time. Nevertheless, 
volume of sweetened-beverage consumption per capita in Sweden has not changed 
significantly after 1995[29].   Second, the age of diagnosis of all our participants was 
above 40 and therefore our findings may not be generalized to earlier onset IBD. Lastly, 
our study may have not been powered to find a more modest association between 
sweetened beverage and risk of IBD. Nevertheless, we estimated that our study had over 
80% power to detect a minimum HR of 1.6 and 1.4 for CD and UC, respectively, figures 
that are significantly higher than previously observed associations between sweetened 
beverage and risk of rheumatoid arthritis in the Nurses’ Health Study (HR = 2.64, 95% 
CI 1.56-4.46 for late-onset RA and HR = 1.63, 95% CI 1.15 – 4.46 for all RA cases) [26]. 
In addition, specific dietary patterns that include high consumption of sweetened-
beverage may be associated with risk of IBD, a possibility that was not explored in the 
current study. 
Our study also had several strengths that are worth noting. First, the prospective 
nature of our study minimized the possibility of selection and recall biases inherent to 
case-control and retrospective cohort studies. Second, dietary data including sweetened 
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beverages from SFFQ have previously been validated against dietary record with good to 
excellent coefficient correlation. Lastly, in our analyses, we were able to account for 
other lifestyle and medications that could have potentially confounded the associations.  
In two large prospective cohort studies we observed no evidence for strong or 
clinically meaningful associations between sweetened beverage and risk of CD and UC. 
Whether sweetened beverages play a role in development of earlier onset IBD (age < 40 
years) is unknown and should be the focus of future investigation.  
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Table 1: Baseline Characteristics of Participants in the Swedish Mammography Study (SMC) and 
Cohort of Swedish Men (CoSM) According to Sweetened Beverage Consumption 
 
 
 
Serving size/day, range (median) 
Q1 
N = 44,750 
 
0 (0) 
Q2 
N = 11,577 
 
0.1 - 0.4 (0.29) 
Q3 
N = 16,311 
 
0.5 – 0.9 (0.86) 
Q4 
N = 10,404 
 
≥ 1.0 (2.0) 
     
Age  (yrs), mean (std) 62 (9) 59 (9) 61 (10) 62 (10) 
     
Body mass index (kg/m2), mean (std) 25 (4) 25 (3) 26 (4) 26 (4) 
     
Smoking     
Never 44 49 48 42 
Past 31 30 30 32 
Current 25 21 22 26 
     
Ever use of NSAIDs, % 48 54 48 55 
     
Total Protein intake (g/day)*, mean (std) 89 (21) 86 (20) 87 (20) 83 (20) 
     
Total Fat intake (g/day) *, mean (std) 76 (21) 75 (19) 77 (19) 74 (19) 
     
Total Fiber Intake (g/day) *, mean (std) 27 (9) 26 (8) 26 (8) 24 (8) 
     
Total Caloric Intake (g/day), mean (std) 2052 (759) 2142 (725) 2348 (796) 2718 (886) 
     
Abbreviations: years (yrs), standard deviation (std). * Values are adjusted for total caloric intake.  
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Table 2: Sweetened Beverage Consumption and Risk of Crohn’s Disease and Ulcerative Colitis* 
 
 
 
Serving size/day, range (median) 
Q1 
N = 44,750 
 
0 (0) 
Q2 
N = 11,577 
 
0.1 - 0.4 (0.29) 
Q3 
N = 16,311 
 
0.5 – 0.9 (0.86) 
Q4 
N = 10,404 
 
≥ 1.0 (2.0) 
 
     Ptrend 
Person-years of follow up 677,440 185,417 249,435 152,274  
      
Crohn’s disease      
Number of cases 70 14 39 20  
Age-adjusted, HR (95% CI) ∆ 1.00 0.96 (0.54-1.71) 1.57 (1.06-2.32) 1.18 (0.72-1.94) 0.11 
MV-adjusted, HR (95% CI) ∆ 1.00 0.95 (0.53-1.69) 1.46 (0.98-2.18) 1.02 (0.60-1.73) 0.34 
      
      
Ulcerative colitis      
Number of cases 185 33 74 54  
Age-adjusted, HR (95% CI) ∆ 1.00 0.84 (0.58-1.22) 1.12 (0.85-1.46) 1.26 (0.93-1.69) 0.13 
MV-adjusted, HR (95% CI) ∆ 1.00 0.84 (0.58-1.22) 1.08 (0.82-1.42) 1.14 (0.83-1.57) 0.40 
*Abbreviations: Multivariable (MV), hazard ratio (HR), confidence intervals (CI). ∆ Models are stratified by cohort (sex) and adjusted 
for age (years), body mass index, smoking (never, past, and current), total caloric intake, total protein intake, total fiber inake, and 
NSAIDs use.  
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Table 3: Sweetened Beverage Consumption and Risk of Crohn’s Disease According to Selected Strata* 
 Risk Per One Daily Serving of Sweetened Beverage Pinteraction 
  
 
Cohort = SMC  0.49 
Cases 55  
Age-adjusted, HR (95% CI)  1.00 (0.76-1.31)  
MV-adjusted, HR (95% CI) ∆ 1.05 (0.79-1.41)  
   
Cohort = CoSM   
Cases 88  
Age-adjusted, HR (95% CI)  1.00 (0.89-1.12)  
MV-adjusted, HR (95% CI) ∆ 0.99 (0.87-1.12)  
   
Age < 60  0.45 
Cases 45  
Age-adjusted, HR (95% CI)  1.14 (1.04-1.25)  
MV-adjusted, HR (95% CI) ∆ 1.02 (0.96-1.09)  
   
Age ≥ 60   
Cases 86  
Age-adjusted, HR (95% CI)  0.88 (0.72-1.08)  
MV-adjusted, HR (95% CI) ∆ 0.89 (0.72-1.11)  
 
  
BMI < 25 kg/m2  0.12 
Cases 77  
Age-adjusted, HR (95% CI)  1.16 (1.04-1.30)  
MV-adjusted, HR (95% CI) ∆ 1.16 (0.98-1.27)  
 
  
BMI ≥ 25   
Cases 66  
Age-adjusted, HR (95% CI)  0.98 (0.83-1.15)  
MV-adjusted, HR (95% CI) ∆ 0.89 (0.74-1.07)  
 
  
Never Smoker  0.33 
Cases 78  
Age-adjusted, HR (95% CI)  1.03 (0.87-1.21)  
MV-adjusted, HR (95% CI) ∆ 0.98 (0.82-1.18)  
 
  
Past/Current Smoker   
Cases 65  
Age-adjusted, HR (95% CI)  1.09 (0.97-1.22)  
MV-adjusted, HR (95% CI) ∆ 1.01 (0.88-1.15)  
*Abbreviations: Multivariable (MV), hazard ratio (HR), confidence intervals (CI). ∆ Models are adjusted for age 
(years), cohort, body mass index, smoking (never, past, and current), total caloric intake, total protein intake, total fiber 
intake, and NSAIDs use. 
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Table 4: Sweetened Beverage Consumption and Risk of Ulcerative Colitis According to Selected Strata* 
 Risk Per One Daily Serving of Sweetened Beverage  
   
 HR (95% CI) Pinteraction 
Cohort = SMC  0.97 
Cases 126  
Age-adjusted, HR (95% CI)  0.89 (0.73-1.10)  
MV-adjusted, HR (95% CI) ∆ 0.92 (0.74-1.13)  
   
Cohort = CoSM   
Cases 223  
Age-adjusted, HR (95% CI)  0.99 (0.98-1.01)  
MV-adjusted, HR (95% CI) ∆ 1.01 (0.94-1.08)   
   
Age < 60  0.18 
Cases 133  
Age-adjusted, HR (95% CI)  1.10 (1.03-1.18)  
MV-adjusted, HR (95% CI) ∆ 1.08 (0.96-1.22)  
   
Age ≥ 60   
Cases 216  
Age-adjusted, HR (95% CI)  1.03 (0.94-1.12)  
MV-adjusted, HR (95% CI) ∆ 0.92 (0.75-1.14)  
 
  
BMI < 25 kg/m2  0.89 
Cases 160  
Age-adjusted, HR (95% CI)  1.09 (0.99-1.21)  
MV-adjusted, HR (95% CI) ∆ 1.03 (0.92-1.15)  
 
  
BMI ≥ 25   
Cases 189  
Age-adjusted, HR (95% CI)  1.07 (1.00-1.15)  
MV-adjusted, HR (95% CI) ∆ 1.03 (0.95-1.11)  
 
  
Never Smoker   
Cases 144 0.18 
Age-adjusted, HR (95% CI)  1.04 (0.92-1.18)  
MV-adjusted, HR (95% CI) ∆ 1.01 (0.88-1.15)  
 
  
Past/Current Smoker   
Cases 205  
Age-adjusted, HR (95% CI)  1.08 (1.02-1.15)  
MV-adjusted, HR (95% CI) ∆ 1.02 (0.95-1.10)  
*Abbreviations: Multivariable (MV), hazard ratio (HR), confidence intervals (CI). ∆ Models are adjusted for age (years), 
cohort, body mass index, smoking (never, past, and current), total caloric intake, total protein intake, total fiber intake, 
and NSAIDs use. 
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